8-KLeadership ChangesOther Events

DEXCOM INC 8-K Report, Executive Changes (Nov 19, 2014)

Filed November 19, 2014For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K report on November 19, 2014, announcing a key change in its Board of Directors. Effective November 17, 2014, the company increased its board size to nine members and appointed Mark G. Foletta as a Class III director. Mr. Foletta's appointment is a strategic move to strengthen board expertise and governance, with his term set to expire at the 2017 Annual Meeting. Investors should note the equity compensation awarded to Mr. Foletta as part of his appointment. He received a one-time restricted stock unit (RSU) grant valued at $300,000, vesting over three years, and a prorated annual retainer RSU grant vesting in May 2015. These grants, made under the 2005 Equity Incentive Plan, align his interests with long-term shareholder value and are subject to acceleration upon a change of control, a common provision designed to protect directors' interests in such scenarios.

Key Highlights

  • 1DexCom increased its Board of Directors size to nine members.
  • 2Mark G. Foletta was elected as a Class III director, with his term expiring at the 2017 Annual Meeting.
  • 3Mr. Foletta's appointment fills a vacancy and is not associated with any disclosed related-party transactions.
  • 4Mr. Foletta received a one-time restricted stock unit (RSU) grant valued at $300,000.
  • 5The $300,000 RSU grant vests over a 36-month period in three equal annual installments.
  • 6Mr. Foletta also received a prorated annual retainer RSU grant, vesting on May 30, 2015.
  • 7All RSU grants are subject to acceleration in the event of a change of control for DexCom.

Frequently Asked Questions

Mark G. Foletta was appointed as a Class III director to the DexCom Board of Directors. The filing does not specify the exact reasons for his appointment beyond filling a vacancy, but such appointments are typically made to bring in relevant expertise, diversify board experience, and enhance corporate governance. His term is set to expire at the 2017 Annual Meeting.

Mr. Foletta received equity compensation in the form of restricted stock units (RSUs). This included a one-time grant valued at $300,000, which vests over 36 months in three annual installments, and a prorated annual retainer grant that vests on May 30, 2015. These RSUs are subject to standard terms under DexCom's 2005 Equity Incentive Plan, including acceleration upon a change of control.

Based on the 8-K filing, Mr. Foletta is not a party to any transaction with DexCom that requires disclosure under Item 404(a) of Regulation S-K. He is also expected to enter into DexCom's standard indemnity agreement for directors and officers, which is customary for board members.

The RSU grants serve to align Mr. Foletta's financial interests with those of DexCom's shareholders. The vesting schedule over multiple years incentivizes long-term performance and retention. The fact that these RSUs are subject to acceleration upon a change of control is a common provision that provides security for directors in potential acquisition scenarios.